Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2022-01-17 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
2022年股票期权激励计划实施考核管理办法0117
Governance Information Classification · 95% confidence The document is titled as the '2022 Stock Option Incentive Plan Implementation Assessment Management Measures' of a company. It details the purpose, principles, scope, assessment institutions, performance evaluation indicators, assessment periods, procedures, and management of assessment results related to a stock option incentive plan. It is a governance-related document focusing on the company's internal rules and mechanisms for stock option incentives and performance assessments. It does not contain financial statements, earnings data, or audit information. It is not an announcement or a report of voting results, nor a regulatory filing or legal proceeding. The content aligns with governance information about internal policies and management practices related to stock option incentives. Therefore, the most appropriate classification is Governance Information (CGR). The document length is 2606 characters, which is not extremely short, and it contains substantive policy content, not just an announcement or certification.
2022-01-17 Chinese
关于2021年第四季度健帆转债转股情况的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the convertible bond (健帆转债) conversion situation for the fourth quarter of 2021 by 健帆生物科技集团股份有限公司. It details the number of bonds converted into shares, the remaining convertible bonds, changes in share capital structure, and related regulatory compliance information. The document is relatively short (2721 characters) and focuses on quarterly convertible bond conversion updates rather than comprehensive financial statements or earnings highlights. It does not contain full financial statements or detailed financial analysis typical of an Interim/Quarterly Report (IR) or Annual Report (10-K). Instead, it is a regulatory announcement about bond conversion and share capital changes, fitting best under Capital/Financing Update (CAP).
2022-01-04 Chinese
关于健帆转债开始转股的提示性公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the start of the conversion period for a convertible bond issued by the company. It includes information about the bond issuance, terms, conversion price, conversion procedures, redemption and repurchase clauses, and shareholder rights post-conversion. The document is regulatory in nature, providing detailed terms and conditions of the convertible bond and related corporate actions. It is not a financial report, earnings release, or management discussion. It is also not a brief announcement or a proxy statement. The document is a formal regulatory announcement about convertible bond conversion and related terms, fitting best under Regulatory Filings (RNS). The document length is 6895 characters, which is substantial and contains detailed information, not just a brief notice or report publication announcement. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2021-12-27 Chinese
第四届监事会第二十六次会议决议公告
Transaction in Own Shares Classification · 95% confidence The document is a formal announcement of a resolution passed at a supervisory board meeting of the company. It details the meeting attendance, the agenda item about the purpose of share repurchase, and the voting results. It references compliance with relevant laws and regulations and mentions that further details are disclosed on an external website. The document is short (715 characters) and does not contain financial statements or detailed financial data. It is not a full report but an announcement of a board decision related to share repurchase. According to the classification rules, announcements about share repurchase or share buyback activities fall under 'Transaction in Own Shares' (POS).
2021-12-24 Chinese
关于确定公司回购股份用途的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement regarding the determination of the purpose of the company's repurchased shares. It details the board and supervisory meetings' approvals, the use of repurchased shares for converting convertible bonds, and confirms that no shareholder meeting approval is required. The document is focused on the company's share repurchase and its intended use, not on financial results or a report. It is not a full financial report, earnings release, or management discussion. It fits the category of a Transaction in Own Shares (POS) as it relates to the company's repurchase and use of its own shares.
2021-12-24 Chinese
独立董事关于第四届董事会第二十八次会议相关事项的独立意见
Transaction in Own Shares Classification · 95% confidence The document is a statement of independent directors providing their opinion on a specific board meeting matter related to the company's share repurchase purpose. It references relevant laws and confirms the legality and fairness of the repurchase plan. The document is short (397 characters) and does not contain financial statements or detailed financial data. It is not a full report but an opinion related to a capital action (share repurchase). This fits best under 'Transaction in Own Shares' (POS), which covers reports related to company buying back or selling its own shares.
2021-12-24 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.